Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Theravance Biopharma has received marketing authorization from the Ministry of Health of the Russian Federation for Vibativ (telavancin) to treat complicated skin and soft tissue infections, as well as nosocomial pneumonia, caused by Gram-positive bacteria, including methicillin-resistance Staphylococcus aureus (MRSA).
Subscribe to our email newsletter
Vibativ is a bactericidal, once-daily antibiotic with in vitro potency and a dual mechanism of action against Gram-positive bacteria.
Russian pharmaceutical firm R-Pharm will be responsible to market and sell Vibativ in Russia from September this year.
Theravance Biopharma Development and Operations senior vice-president Frank Pasqualone said: "We are pleased that healthcare practitioners in Russia will now be able to add Vibativ to their antibiotic choices, especially for those difficult-to-treat Gram-positive bacteria, such as MRSA, against which the drug has been shown to be an effective treatment.
"At the same time, this is another key achievement for Theravance Biopharma, highlighting the value of strategic collaborations with partners, such as R-Pharm, in our efforts to build the global brand and expand the commercial reach of Vibativ into target markets outside the US."
The marketing approval triggers a milestone payment to Theravance under terms of its development and commercialization agreement with R-Pharm.
Under this deal, Theravance will also receive potential future contingent payments and a royalty on net sales of Vibativ from R-Pharm.